Abstract
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight- Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Keywords: CSPG4, immunotherapy, monoclonal antibody, cancer stem cells
Current Molecular Medicine
Title: CSPG4 in Cancer: Multiple Roles
Volume: 10 Issue: 4
Author(s): X. Wang, Y. Wang, L. Yu, K. Sakakura, C. Visus, J.H. Schwab, C.R. Ferrone, E. Favoino, Y. Koya, M.R. Campoli, J.B. McCarthy, A.B. DeLeo and S. Ferrone
Affiliation:
Keywords: CSPG4, immunotherapy, monoclonal antibody, cancer stem cells
Abstract: Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight- Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Export Options
About this article
Cite this article as:
Wang X., Wang Y., Yu L., Sakakura K., Visus C., Schwab J.H., Ferrone C.R., Favoino E., Koya Y., Campoli M.R., McCarthy J.B., DeLeo A.B. and Ferrone S., CSPG4 in Cancer: Multiple Roles, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791316977
DOI https://dx.doi.org/10.2174/156652410791316977 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Of Man in Mouse: Modelling Human Cancer Genotype-Phenotype Correlations in Mice
Current Genomics Natural and Engineered Cystine Knot Miniproteins for Diagnostic and Therapeutic Applications
Current Pharmaceutical Design Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Molecular Imaging Probe Development Using Microfluidics
Current Organic Synthesis Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Current Drug Discovery Technologies The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry HIV-1 IN Inhibitors: 2010 Update and Perspectives
Current Topics in Medicinal Chemistry Hierarchy of Knowledge Translation: From Health Problems to Ad-Hoc Drug Design
Current Medicinal Chemistry Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by NanoRNA Oligonucleotides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lipoamino Acid Prodrugs of Paclitaxel: Synthesis and Cytotoxicity Evaluation on Human Anaplastic Thyroid Carcinoma Cells
Current Cancer Drug Targets Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors
Current Drug Targets The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging A Review of Pharmacological and Phytochemical Studies on Convolvulaceae Species <i>Rivea</i> and <i>Ipomea</i>
Current Traditional Medicine Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis
Current Pharmaceutical Design